# Champions Oncology, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Champions Oncology, Inc). ## Overview Champions Oncology, Inc. is a U.S.-based oncology technology and services company that evolved from a sports restaurant business into a biotechnology platform focused on cancer drug development. The company combines translational oncology research services with proprietary experimental and computational tools designed to help pharmaceutical and biotechnology customers personalize oncology drug development. Its core platform includes TumorGraft-based models, biomarker capabilities, and software/data-license offerings under its Translational Oncology Solutions (TOS) umbrella. In parallel, Champions is building an internal drug discovery and development pipeline that uses AI and experimental validation to identify and advance novel therapeutic targets. The business is still relatively small and capital constrained, but it has established direct commercial relationships with drug developers and is trying to expand both recurring research revenue and the value of its discovery assets. ## Products & services • Pharmacology services for oncology research programs • TumorGraft-based translational oncology studies • Translational Oncology Solutions (TOS) software and data licenses • Biomarker and experimental validation platforms • Drug discovery and development programs • Computational analytics and AI-enabled target identification - **Research Services** (85%) — Preclinical oncology studies and pharmacology services sold to drug developers to support target evaluation and translational research. - **TOS Data and Software Licensing** (8%) — Licenses for translational oncology software, datasets, and related data-access products. - **Other TOS Revenue** (7%) — Ancillary revenue from additional translational oncology services and platform-related work. - **Drug Discovery and Development** (0%) — Internal R&D programs aimed at identifying and validating therapeutic targets for future partnering or commercialization. - Pharmacology services for oncology research programs - TumorGraft-based translational oncology studies - Translational Oncology Solutions (TOS) software and data licenses - Biomarker and experimental validation platforms - Drug discovery and development programs - Computational analytics and AI-enabled target identification ## Customers Champions sells primarily to pharmaceutical and biotechnology companies that need outsourced oncology research to evaluate drug candidates and improve development decisions. These customers use the company’s pharmacology and translational platforms to test how tumors respond, validate targets, and generate data that can de-risk early-stage programs. The company also serves users of its TOS software and data products, which are bought for access to proprietary oncology datasets and computational tools. Its drug discovery work is not yet a major external revenue stream, but it is strategically aimed at future partnering, spin-outs, or capital-raising opportunities. Customer demand is driven by the need for specialized oncology models, faster decision-making, and access to differentiated experimental data that many customers cannot efficiently build in-house. - **Pharmaceutical companies** (primary) — Buy pharmacology and translational oncology studies to evaluate drug candidates, validate targets, and support development decisions. - **Biotechnology companies** (primary) — Use the company’s research services and data tools to de-risk early oncology programs and accelerate preclinical work. - **TOS software and data users** (secondary) — Purchase licenses for proprietary oncology datasets, computational tools, and related translational insights. - **Internal drug discovery partners** (emerging) — Potential future partners or acquirers of validated targets and therapeutics emerging from the company’s discovery pipeline. - Pharmaceutical companies outsourcing preclinical oncology studies - Biotechnology firms evaluating early-stage cancer drug candidates - Customers buying TOS licenses for oncology data and software access - Research teams seeking TumorGraft and biomarker validation capabilities - Drug developers needing translational evidence to support target selection - Organizations that prefer external expertise over building in-house platforms ## Geography Champions is headquartered in the United States and appears to generate the vast majority of its revenue from U.S.-based customers, although the filings provided do not disclose a formal geographic revenue split. Its commercial model is centered on direct sales to pharmaceutical and biotechnology customers, which are often global but frequently managed through U.S. operating relationships. The company also faces competition from U.S. and international peers, so its market exposure is not limited to domestic competitors. Operationally, the business depends on laboratory, animal-testing, and computational infrastructure, which are typically concentrated in the U.S. and create cost exposure to local labor, facility, and compliance conditions. Because no country-level revenue table was disclosed in the excerpts, the geographic breakdown is estimated conservatively and should be treated as non-authoritative. - **United States** (90%) — Estimated from U.S. headquarters and U.S.-centric customer base; no disclosed country revenue table in excerpts. - **International** (10%) — Estimated residual exposure from global biopharma customer base and international competition. - Headquartered in the United States - Revenue appears predominantly U.S.-based, but no country split was disclosed - Competes with U.S. and international oncology research providers - Laboratory and animal-testing operations create local facility and staffing exposure - Commercial relationships are with global biopharma customers, often managed from the U.S. ## Strategy Champions is trying to grow its research-services franchise by increasing the number of studies per customer and the average study size, while also winning new pharmaceutical and biotechnology accounts. Management has highlighted operational improvements and better bookings-to-revenue conversion as a key lever for revenue growth, which matters because signed statements of work convert into revenue over time as projects are completed. The company is also expanding TOS data-license revenue, which can improve product mix and create more scalable monetization of its oncology data assets. In parallel, it is investing in drug discovery and development using AI, computational analytics, and proprietary experimental platforms to identify novel targets and build a pipeline of validated assets. The company continues to evaluate strategic alternatives for that discovery business, including spin-outs or capital raises, suggesting a capital-allocation strategy that may separate service revenue from higher-risk R&D assets. - **Improve bookings-to-revenue conversion** (short-term) — Faster and more reliable conversion of signed work into revenue supports growth without requiring proportional increases in fixed cost. - **Grow TOS data-license revenue** (medium-term) — Licensing can improve scalability and diversify the revenue mix beyond project-based research services. - **Advance drug discovery pipeline** (medium-term) — Validated targets and therapeutics could create higher-value partnering or monetization opportunities than services alone. - Increase study volume and average study size in research services - Convert more signed statements of work into recognized revenue - Expand TOS data-license revenue as a more scalable product line - Use AI and computational analytics to identify novel oncology targets - Advance validated targets into therapeutic development - Evaluate spin-outs or capital raises for the discovery business ## Risks Champions remains exposed to the risk that it may need additional capital, because management has disclosed a history of losses, accumulated deficits, and periods of negative working capital or limited cash. Its revenue is concentrated in research services, so demand swings, study cancellations, and slower bookings-to-revenue conversion can materially affect quarterly results. The company also competes against much larger healthcare, biopharma, software, and open-source alternatives, which can pressure pricing, customer retention, and talent recruitment. Drug discovery programs are inherently uncertain and may never be commercialized, so R&D spending can fail to produce offsetting revenue or asset value. In addition, the business depends on laboratory, animal-testing, and IT systems, making it vulnerable to cybersecurity incidents, operational disruptions, regulatory delays, and broader macro shocks such as inflation, higher interest rates, supply-chain issues, and geopolitical instability. - **Going concern / financing risk** [high] — Management disclosed accumulated deficits, limited cash, and the possibility of needing additional equity or debt capital to continue operations. - **Revenue concentration in research services** [high] — Most revenue is derived from project-based oncology research services, making results sensitive to bookings, cancellations, and customer budget cycles. - **Commercialization risk in drug discovery** [high] — Early-stage targets may fail technical validation or never become marketable therapeutics, limiting return on R&D spend. - **Competition from larger and lower-cost alternatives** [medium] — The company competes with larger healthcare firms, scientific software vendors, in-house customer teams, and open-source tools. - **Cybersecurity and IT disruption** [medium] — The business relies on cloud-based and internal systems for data, billing, and operations, so breaches or outages could disrupt service delivery. - Potential need for additional financing to fund operations - Revenue volatility from project timing and study cancellations - Intense competition from larger oncology and software providers - Drug discovery programs may not reach commercialization - Dependence on specialized scientific personnel and facilities - Cybersecurity and data-privacy risks affecting proprietary data and systems - Macro and geopolitical disruptions can affect customer spending and operations ## Accounting Revenue recognition is a key accounting issue because research services are fulfilled over time as contractual performance obligations are completed, while TOS data-license revenue is recognized when licenses are sold. That means quarterly revenue can move with bookings conversion, study cancellations, and the timing of project milestones rather than with simple customer demand. The company also discloses deferred revenue as an important driver of operating cash flow, so changes in contract liabilities can make cash generation look different from reported earnings. Stock-based compensation, accounts receivable collectability, and lease accounting are additional judgment areas that affect reported expenses and working capital. Because the drug discovery business is expensed as incurred, investors should expect R&D spending to flow through the income statement before any future monetization is visible. - **Revenue recognition timing** — Quarterly revenue and margin volatility - **Deferred revenue** — Cash flow versus earnings comparability - **Stock-based compensation** — Reported operating profit and dilution - **Accounts receivable realization** — Working capital and bad-debt expense - Over-time revenue recognition for research services affects quarterly comparability - TOS data-license revenue is recognized separately from service revenue - Deferred revenue influences cash flow versus reported earnings - Accounts receivable realization requires judgment on collectability - Stock-based compensation affects operating expenses and non-cash charges - Drug discovery costs are expensed as incurred, depressing near-term earnings --- *Last updated: 2026-09-24T12:11:06.787111+00:00*